In this study, the potential cardioprotective properties of novel lipophilic aroylhydrazone chelators (pyridoxal 2-chlorobenzoyl hydrazone, salicylaldehyde isonicotinoyl hydrazone) as well as dexrazoxane (model cardioprotectant) and deferiprone (novel clinically used iron chelator) were studied on the rabbit model of chronic anthracycline cardiotoxicity.